Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ketamine + dexamethasone is a combination of two pharmaceutical agents used primarily as adjuvants in anesthesia and pain management. Ketamine is a rapid-acting general anesthetic and NMDA receptor antagonist, while dexamethasone is a potent synthetic corticosteroid with anti-inflammatory and immunosuppressant properties. When administered together, typically intravenously or as additives to local anesthetics (such as lidocaine or bupivacaine), this combination has been shown to prolong the duration of analgesia, reduce postoperative pain scores, and improve mood outcomes after surgery. The mechanism involves ketamine’s blockade of NMDA receptors leading to analgesia and antidepressant effects, while dexamethasone acts via glucocorticoid receptor-mediated inhibition of pro-inflammatory pathways[3][4][6]. This combination has been studied in various surgical settings including gynecologic surgery, pediatric abdominal operations, and regional nerve blocks[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ketamine + dexamethasone.